Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 61, Issue 10, Pages 4290-4300Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.7b01310
Keywords
-
Categories
Funding
- National Natural Foundation of China [81622043, 81773579]
- Natural Science Foundation of Zhejiang Province [LR16H310001, LY17B020008]
Ask authors/readers for more resources
The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC). The current third-generation EGFR small-molecule inhibitors, especially osimertinib, are at the forefront clinically for treatment of patients with NSCLC. However, a high percentage of these treated patients developed a tertiary cystein-797 to serine-790 (C797S) mutation in the EGFR kinase domain. This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs. In this Miniperspective, we present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance. Specifically, we analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations. Lastly, we provide some perspectives on new challenges and future directions in this field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available